BioPharmSignal logoBioPharmSignal

Biotech News

Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma

Roche Holdings AG (RHHBY)Roche Holdings AGCommercial

Basel, 28 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the global launch of the VENTANA BAP1 (SP527)* test. This automated, ready-to-use immunohistochemistry (IHC) assay provides a reliable, highly specific diagnostic tool to help clinicians and pathologists accurately identify mesothelioma and distinguish it from other malignancies, including non-small cell lung cancer (NSCLC). The BAP1 assay is registered as a Class I IVD with U.S. Food and Drug Administration, has received IVDR approval as a Class C device, and is available globally.

Related news

RHHBYRoche Holdings AG2026-10-27 06:00 EST

Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories

RHHBYRoche Holdings AG2026-10-19 05:00 EST

Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio

REPLReplimune Group2026-10-01 20:01 EST

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

SNDXSyndax Pharmaceuticals2026-10-30 13:01 EST

Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases

SNDXSyndax Pharmaceuticals2026-10-15 20:01 EST

Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List

RVMDRevolution Medicines2026-10-27 20:05 EST

Revolution Medicines to Participate in November 2026 Investor Conferences

SNYSanofi2026-10-12 16:05 EST

Sanofi: Information concerning the total number of voting rights and shares – September 2026

RVMDRevolution Medicines2026-10-20 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer

GSKGSK plc2026-10-18 19:36 EST

GSK presents first global data for Ris-Rez in extensive-stage small cell lung cancer

BMYBMYBristol-Myers Squibb Company2026-10-29 10:59 EST

Bristol Myers Squibb Reports Third Quarter Financial Results for 2026

View all latest news

Roche Holdings AG

Integrated Pharmaceuticals and Diagnostics Company Roche is a global healthcare company that combines prescription medicines, diagnostic systems, and digital technologies within a single research and commercial organization. The group operates through Pharmaceuticals and Diagnostics divisions, with Genentech serving as its wholly owned...

Recent company news

RHHBYRoche Holdings AG2026-10-28 06:00 EST

Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma

RHHBYRoche Holdings AG2026-10-27 06:00 EST

Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories

RHHBYRoche Holdings AG2026-10-25 15:30 EST

Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer

RHHBYRoche Holdings AG2026-10-23 17:30 EST

Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

RHHBYRoche Holdings AG2026-10-21 12:00 EST

Roche presents new pivotal trial data across broad neuroimmunology portfolio at MSToronto2026

Stock data

Close
59.45 USD
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States